Category: eClinical Solutions

13 Sep 2018


Apple launched a large-scale heart rate study in collaboration with Stanford Medicine in November 2017. The study (called Apple Heart Study) was conducted to improve technology that identifies irregular heart rhythms. Early diagnosis and treatment can prevent life-threatening heart complications, including strokes.

The study was carried out in the form of an app, open to all Apple Watch owners in the United States, 22 years and older, with a Series 1 or above. It measured heart rhythm and heart rate using the Apple Watch’s LED sensor and light-sensitive photodiodes to detect the amount of blood flowing through a person’s wrist. It was able to isolate heart rhythms from other noise in order to detect irregular heartbeats, with the use of AI technology.

The study was closed to new participants at the start of last month, with Apple also informing some users who signed up that their contribution is complete. The end is in sight as the study is expected to come to a conclusion in January 2019.

It is still unclear as to what Apple and Stanford Medicine will do with the results from their study, and if it will be utilized to equip future Apple Watch devices to bring the results into effect.

For more information visit Cult of Mac

20 Jul 2018


It’s an exciting time as the industry takes hold of clinical trial technology.
eSource, by extending eClinical functionality to the site level, is a key component of the future of clinical research and equips organizations with efficiencies that brings about higher trial volume and lower margins. This technology has led to unparalleled efficiencies in data capture and monitoring.

eClinical technology users and providers should act now to be ahead of the game as eSource continues to spread. There is a full range of benefits that the platform has to offer, including increased productivity, enhanced competitive edge, cost saving as well as time-saving. Move quickly in order to maintain a competitive advantage.

For more information, visit: Clinical Leader

02 May 2017

TCD joins EOH as the group grows with strategic changes taking effect in May 2017

We are delighted to share the following significant changes and positive developments which took place recently within the TCD Group.

New Ownership

EOH, a JSE-listed South African based Knowledge Management group, have been in negotiation with the TCD Group since the last quarter of 2015, sharing the strategic objective to expand in the field of healthcare. EOH consists of a diverse portfolio of specialised industries in 21 countries across four continents.

The groups came to agreement in October 2016 and the transaction was completed in February 2017. EOH Holdings is now the 100% shareholder of the TCD Group of companies. We are excited by this positive development which opens many new horizons through the global profile of our new proudly South African owners.

The EOH philosophy involves sustaining successful acquisitions by building upon the inherent culture. The TCD Group will remain easily recognisable, building on our rich legacy, striving as always for continuous improvement.

Expansion of the TCD Group

The rapid evolution of the TCD Group expanded the original Triclinium into a full-service CRO (Contract Research Organisation), with a growing range of services and geographical footprint. Triclinium’s sister companies, within the TCD Group now consists of:

  • TCD Outcomes Research: The TCD Group developed a Health Economics and Outcomes Research (HEOR) organisation, through an acquisition of HeXor (a late phase development and pharmacoeconomics company), combined with the Late Phase Clinical Development expertise of TCD.
  • TCD e-Clinical Solutions: The TCD Group created an e-Clinical Solutions division which includes Software as a Service solution. TCD e-Clinical Solutions is focused around improving the outcome of clinical trials from a quality and efficiency perspective. Services include Electronic Data Capture (EDC), Electronic Medical Records (EMR), Electronic Patient Reported Outcomes (ePRO), Electronic Clinical Outcome Assessments (eCOA) and Mobile Health (mHealth), etc.
  • TCD Global Data Services: The TCD Group established and consolidated its Data Management and Biostatistics division under the TCD GDS brand, which is spearheaded out of South Africa and Bangalore, India.
  • TCD-MENA: The TCD Group established a full-service CRO based in Cairo, Egypt through a Joint Venture to focus on the Middle East and North Africa region.
  • PharmaLTX: The TCD Group established a software development company which specialises in software solutions in the wider health care sector such as partnering with Ministries of Health, Regulatory agencies, Institutional Review Boards, Universities, Clinical Research Centres, etc.


New TCD Group Chairman

The mandate to meld the member companies into a synergistic group has been entrusted to Dr Tienie Stander, founder of HeXor Pty Ltd., current Managing Director of TCD Outcomes Research, and now also the inaugural Chairman of the TCD Group.

Change in Managing Director of Triclinium Clinical Development

To those who know the company well, the most visible change is that after 17 years at the helm, founder Victor Strugo will relinquish the position of Managing Director to Abraham van Wyk, effective 1st May, 2017. Abraham has been increasingly involved in TCD executive functions since 2014 and his promotion is fully endorsed by TCD’s Board of Directors.

Victor will nevertheless remain active and visible in the new role of TCD Group Strategic Adviser, facilitating a smooth management transition, supporting key projects and developing new horizons for the company that he created in February 2000.

Our electronic media will be updated accordingly over time. We look forward to maintaining and strengthening our association with your organisation through this transition and to offer an ever-improving and broadening range of services in the years ahead.

For queries or more information, contact us at

28 Dec 2016

Exciting technology trends for clinical trials in 2017

“A lot has happened in the clinical trials industry in 2016, as biopharmaceutical enterprises are just starting to delve into clinical trial innovation. Risk Based Monitoring (RBM) is starting to expand into new concepts in Quality Risk Management; enterprises have aggregated their data to generate clinical trial predictive models; the definition of patient centricity is cementing; incorporating endpoint adjudication methodologies in trial design is talked about often; subject enrollment is increasing in efficiency and scalability through big data, and mHealth pilots are starting to demonstrate promising data.” – Moe Alsumidaie, Author at Applied Clinical Trials.

Read the full article at

[source : Moe Alsumidaie –]

18 Nov 2016

How 3-D printing can save lives in the medical field

For most people the concept of three-dimensional (3D) printing is still seen as something from a science fiction novel, but the medical world is busy embracing this technology and is a major driving force behind its growth.

Dr Thomas Bartel, section head of the Heart and Vascular Institute at Cleveland Clinic Abu Dhabi said the following : “In health care, 3-D printing’s most impressive function is its ability to replicate organs to help plan for or simulate surgeries. 3-D printing helps us personalise care while minimising risk.”

The costs related to 3-D printing have dropped considerably over the past 2 years and, according to consultants Frost & Sullivan, the 3-D printing industry alone will become a $6 billion market by 2025.

For the full article please visit :

[image source :]

25 Oct 2016

Health tech startup Cardiogram screens users’ cardio health using wearable device

“In the last six months, we’ve gathered more than 10 billion sensor measurements from more than 100,000 contributors. Of course, raw sensor data is not a biomarker, a biomarker is not a diagnosis, and a diagnosis is not a therapeutic,” co-founder of Cardiogram Brandon Ballinger wrote in a blog post.

“This volume of data has let us achieve a c-statistic (an accuracy measure) of above 90% in detecting atrial fibrillation, the most common abnormal heart rhythm,” Ballinger said. “We think it’s important for even young digital health companies to submit their work to peer review, so you’ll see us submit to both medical journals and artificial intelligence conferences in coming years as well.”

For the full article please visit :

[image source :]

11 Oct 2016

How mHealth Technology Supports Patient Engagement Strategies

mHealth (mobile Health) is more and more becoming the standard when it comes to Patient Reported Outcomes (ePRO) or patient engagement in the discipline of pharmacovigilance. According to the Center for Connected Health Policy, remote patient monitoring is the use of “digital technologies to collect medical and other forms of health data from individuals in one location and electronically transmit that information securely to health care providers in a different location for assessment and recommendations.”

Capital Blue Cross conducted a study in 2016 and their research found that when heart failure patients used remote patient monitoring devices, it cut hospitalizations by nearly one-third. “Not only is chronic disease expensive, difficult to manage and a drain on our healthcare system, but it also takes a toll on patients and families, decreasing their quality of life and often leading to an accelerated transition out of the home and into facility-based care,” said Jennifer Chambers, MD, Chief Medical Officer at Capital Blue Cross.

For the full article please visit :

26 Sep 2016

Microsoft helping to find cancer treatments

The Microsoft corporation is assisting the oncology team at the Australian National University (ANU) to uncover more about the genomics of cancer. This process will help identify which genes have been affected in a negative way in the genome. “The collaboration between biologists and computer scientists is actually key to making this work,” Microsoft’s corporate vice-president Jeannette Wing said.

Cheng Soon Ong , an adjunct associate professor at ANU and principal research scientist at CSIRO, said a clearer understanding on genomics would allow for more targeted treatment. “Once you have been diagnosed with cancer your genomics can give indications to the doctor [as to] which treatment you’re more likely to respond to,” Professor Soon Ong said.

For the full article please visit :

30 Aug 2016

Digital Healthcare Market Growth

The growth of the digital healthcare market has been steady over the past 10 years but in recent times this growth curve has changed exponentially. The introduction and adoption of mobile applications and wearable devices related to wellness and healthcare have been one of the main drivers behind this.

“Mobile network operators view mHealth as a lucrative opportunity for the monetization of their mobile connectivity services as a growing proportion of their subscribers adopt healthcare-centric wearables.  Given that most operators have established themselves as reputable consumer brands, they are also eyeing on opportunities to offer services beyond simple connectivity. Many operators already offer branded or co-branded end-to-end mHealth solutions to their customer bases.” according to research done by the team at ReportsnReport. []. Driven by the thriving ecosystem, research estimates that the mHealth market will account for nearly $18 Billion in 2016 alone.

For the full story regarding trends in the digital healthcare space please visit :

09 Aug 2016

CDISC and TransCelerate Announce New Standard for Breast Cancer

TransCelerate BioPharma Inc.(“TransCelerate”) is a non-profit organisation dedicated to improving the health of people around the world by accelerating and simplifying the research and development (R&D) of innovative new therapies.The Clinical Data Interchange Standards Consortium (CDISC) is a 501(c)(3) global non-profit charitable organisation that streamlines research and enables connections to healthcare through the development of clinical research data standards.

The need to rapidly and efficiently share new data within clinical research is one of the key initiatives within the world of clinical trial innovation and efficiencies. One of the major steps forward is the announcement CDISC and TransCelerate made earlier this year regarding the open availability of a new CDISC Therapeutic Area Standard for Breast Cancer.

“In order to optimize the care of any patient, we need to have a common set of information that is reliably collected on every one,” stated Dr. Laura Esserman, University of California San Francisco breast cancer surgeon and one of Time magazine’s top 100 most influential individuals in the world. “The CDISC standards will help us to ensure that we are all using a common language, which will then usher in an era where we can automate quality improvement, trial matching, seamless integration of data into trials, and streamline the process of improving the care, survival, and quality of life of our patients.”

For the full article please visit :